SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) August 17, 2000
BICO, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
2275 Swallow Hill Road, Bldg. 2500, Pittsburgh, Pennsylvania 15220
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 429-0673
Former name: Biocontrol Technology, Inc.
__________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today that
it has received FDA approval to begin a multi-
center, controlled clinical study for its
noninvasive glucose monitor, the Diasensor 2000.
Biocontrol received the approval following the
FDA's review of the company's Investigational
Device Exemption (IDE) application. An IDE is a
request to the FDA for approval to conduct human
clinical studies using an unapproved device and
contains a clinical protocol for conducting the
study. The study will be coordinated under the
direction of the Joslin Diabetes Center of Boston.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial
Information and Exhibits.
(a) Financial Statements and Businesses Acquired -
Not Applicable.
(b) Pro Forma Financial Information -
Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange
Act of 1934, the Registrant has duly caused this Report to
be signed on its behalf by the undersigned hereunto duly
authorized.
BICO,INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: August 17, 2000
NEWS RELEASE
BIOCONTROL TECHNOLOGY, INC.
625 Kolter Drive , Indiana, PA 15701
Investors: Media:
Diane McQuaide Nancy Saxman
Phone 412-429-0673 Phone 724-349-1811
Fax 412-279-9690 Fax 724-349-8610
For immediate release
BIOCONTROL TECHNOLOGY RECEIVES FDA OKAY TO BEGIN DIASENSOR
CLINICAL TRIALS
Pittsburgh, Pa. - August 17, 2000 - Biocontrol
Technology, Inc., a division of BICO, Inc. (OTCBB:BICO),
announced today that it has received FDA approval to begin a
multi-center, controlled clinical study for its noninvasive
glucose monitor, the Diasensor 2000. Biocontrol received
the approval following the FDA's review of the company's
Investigational Device Exemption (IDE) application. An IDE
is a request to the FDA for approval to conduct human
clinical studies using an unapproved device and contains a
clinical protocol for conducting the study.
The study will be coordinated under the direction of
the Joslin Diabetes Center of Boston. The Diasensor 2000
will be evaluated for the treatment of diabetic patients
within a system of care that includes home use of the
Diasensor and regular evaluation of a patient's blood
glucose trends as determined by the device. The
Diasensor contains a telemedicine feature that automatically
transmits the patient's glucose measurements to a secure
website on the Internet where they can be viewed by the
healthcare provider.
Joslin Diabetes Center is an international leader in
diabetes treatment, research, and education. Established in
1898, Joslin is affiliated with Harvard Medical School. It
leads the field in both basic and clinical research and in
education of patients and professionals. Joslin is
headquartered in Boston and has facilities throughout
Massachusetts, as well as affiliated diabetes treatment
centers throughout the U.S. Further information on Joslin
Diabetes Center can be found at www.joslin.org.
Biocontrol Technology, Inc. has research, development
and manufacturing facilities in Indiana, Pa. BICO's
corporate offices are located in Pittsburgh, Pa. BICO is
involved in the development and manufacture of biomedical
devices and environmental products.
#####
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1-800-357-6204
This press release contains statements of a forward-looking
nature. Shareholders and potential investors are cautioned
that such statements are predictions and actual events or
results may vary significantly.
